Paris – Iktos, a leading provider of artificial intelligence solutions for drug discovery, is pleased to announce it has become an Advanced Technology Partner in the AWS Partner Network and joined the AWS ISV (Independent Software Vendor) Accelerate co-sell program. As part of this collaboration, Iktos has made Makya, its innovative de novo drug design tool, available on the AWS Marketplace.

This milestone ensures that pharmaceutical companies worldwide can easily access Makya, leveraging AWS’s robust cloud infrastructure for scalable and efficient drug design.

The inclusion of Iktos in the AWS ISV Accelerate program further solidifies this collaboration. Through this initiative, Iktos will expand its reach, deliver enhanced solutions to customers, and optimize performance by leveraging AWS’s secure and scalable resources.

Makya is a generative AI platform that streamlines the drug discovery process. Designed by chemists for chemists, it facilitates the rapid generation of diverse, novel, and medicinal chemistry-like molecules that converge efficiently toward viable drug candidates.

“Our partnership with AWS and the inclusion of Makya on AWS Marketplace represent a significant milestone for Iktos,” said Nicolas Do Huu, CTO & Co-Founder at Iktos. “AWS’s secure and robust cloud infrastructure allows us to deliver Makya’s advanced drug design capabilities to pharmaceutical customers worldwide, enhancing their ability to innovate and transform drug discovery processes. The global reach, scalability, and cutting-edge analytics services provided by AWS were
key factors in our decision to collaborate.”

One of the early adopters of Makya, Teijin Pharma, has successfully deployed the tool within the Iktos infrastructure through AWS, showcasing the tangible benefits of this collaboration. Using AWS’s global cloud infrastructure, Teijin Pharma can efficiently harness Makya’s cutting-edge capabilities, enabling accelerated drug discovery and innovation.

“Teijin Pharma has successfully implemented Makya through AWS to streamline our drug discovery processes,” said Jun Hirata, Director, Teijin Pharma. “The synergy between Iktos’s AI platform and AWS’s reliable, scalable cloud services has allowed us to accelerate molecule design and potentially bring new therapies to the market more efficiently. In particular, Makya, whose user-friendly interface is crafted to enhance our compound design workflow, is available for users of all levels, including medicinal chemists and computational chemists. With its intuitive interface, this software allows for the design of rational compounds, as well as flexible and logical analysis and filtering, rapidly and iteratively. It prioritizes the most promising compounds and significantly contributes to enhancing creativity and productivity. ”

As an Advanced Technology Partner in the AWS Partner Network, Iktos brings significant benefits to pharmaceutical customers, including:
● Global Accessibility: Makya is easily accessible to researchers and teams across the globe, ensuring smooth deployment regardless of geographic location.
● Optimized IT Infrastructure: AWS provides a scalable and secure cloud environment tailored to meet the computational needs of Makya users, allowing them to focus on innovation without worrying about hardware limitations.
● Enhanced Computational Power: With AWS’s powerful cloud computing capabilities, users can run complex simulations and molecule generations efficiently and cost-effectively.
● Accelerated Discovery: Iktos customers, such as Teijin Pharma, demonstrate how this partnership enables faster drug discovery and improves overall productivity.

“We are excited to welcome Iktos as an Advanced Technology Partner to the ISV Accelerate program and support the global deployment of Makya,” said Boris Bogdan, Director of Life Sciences at AWS. “By combining Iktos’s expertise in AI-driven drug discovery with AWS’s scalable and secure cloud infrastructure, we are enabling pharma customers to accelerate their R&D efforts and achieve
transformative outcomes.”

About Iktos
Iktos is a global leader in artificial intelligence and robotics for drug discovery. Its generative AI technology designs molecules in silico, optimized to meet all key success criteria of a discovery project. Available as SaaS software and through strategic collaborations with pharmaceutical companies, Iktos combines AI-driven molecular design with robotic synthesis and biological testing, accelerating drug discovery. With over 60 successful projects to date, Iktos is also advancing its own
pipeline of drug candidates in oncology, obesity and metabolism, inflammatory and autoimmune diseases. Iktos completed a €15.5M Series A financing round, co-led by M Ventures and Debiopharm Innovation, with participation from Omnes Capital.

For more information, visit Iktos.ai.

About Amazon Web Services
Since 2006, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud. AWS has been continually expanding its services to support virtually any workload, and it now has more than 240 fully featured services for compute, storage, databases, networking, analytics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, media, and application development, deployment, and management from 114 Availability Zones within 36 geographic regions, with announced plans for 12 more Availability Zones and four more AWS Regions in New Zealand, the Kingdom of Saudi Arabia, Taiwan, and the AWS European Sovereign Cloud. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government
agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com.

About Teijin Group
Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high performance materials and healthcare solutions. Established in 1918 as Japan’s first rayon manufacturer, Teijin today comprises some 170 companies employing 20,000 people in 20 countries. Teijin is committed to its Purpose, “Pioneering solutions together for a healthy planet.” Teijin works together with employees and external partners to achieve its Long-Term Vision, “To be a company that supports the society of the future.” Teijin posted consolidated sales of JPY 1,032.8 billion (USD 6.6 billion) and total assets of JPY 1,251.0 billion (USD 8.0 billion) in the fiscal year ending March 31, 2024.